Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KIF5B | P33176 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31729256 | 0.86 | PIK3CA (0.33) | PIK3CAMTORHTTKMT2A | |
| SCHEMBL29611762 | 0.85 | PIK3CA (0.49) | PIK3CAMTORMAPTHTTKMT2A | |
| SCHEMBL8916 | 0.85 | PIK3CA (0.49) | PIK3CAMTORMAPTHTTKMT2A | |
| SCHEMBL26603008 | 0.80 | HPGD (0.38) | HTTKMT2AKDR | |
| SCHEMBL31087476 | 0.80 | HPGD (0.38) | HTTKMT2AKDR | |
| SCHEMBL31255306 | 0.80 | SYK (0.36) | PIK3CAMTORMAP2K1EGFRKDR | |
| SCHEMBL12675576 | 0.80 | CYP3A4 (0.45) | PIK3CAMTORMAPTKMT2AEGFR | |
| SCHEMBL31087498 | 0.79 | MET (0.38) | HTTKMT2ACYP3A4 | |
| SCHEMBL26602992 | 0.79 | MET (0.38) | HTTKMT2ACYP3A4 | |
| SCHEMBL12093598 | 0.78 | PIK3CA (0.44) | PIK3CAMTORMAPTCASP1PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719597-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-08 | — | — | US | disclosed |
| CN-119841806-A | Polysubstituted quinazoline compound, preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025070748-A1 | ENHANCER REAGENT FOR CHEMILUMINESCENT REACTION, AND COMPOUND | 富士フイルム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20250084036-A1 | COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND THERAPEUTIC AND/OR PROPHYLACTIC DRUG | ALCHEMEDICINE, INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4512468-A1 | COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND TREATMENT AND/OR PREVENTATIVE DRUG | Alchemedicine, Inc. (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| CN-102245574-A | Compounds, pharmaceutical compositions and methods for treating metabolic disorders | EUROSCREEN SA | 2011-11-16 | — | — | CN | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-4931452-A | N-cyanomethyl-2-pyridinone insecticides | THE DOW CHEMICAL COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| CN-1034715-A | N-cyanogen methyl-2-pyridinone insecticides | DOW CHEMICAL CO (US) | 1989-08-16 | — | — | CN | disclosed |
| WO-1989004301-A1 | N-CYANOMETHYL-2-PYRIDINONE INSECTICIDES | THE DOW CHEMICAL COMPANY (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0316185-A2 | N-cyanomethyl-2-pyridinone insecticides | THE DOW CHEMICAL COMPANY (US) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | PIK3CA 915/4885MTOR 3966/4885MAPT 3282/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | PIK3CA 721/4885MTOR 391/4885MAPT 2878/4885 |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | PIK3CA 598/4885MTOR 2365/4885MAPT 1815/4885 |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | PIK3CA 930/4885MTOR 810/4885MAPT 1763/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CA 1/4885MTOR 25/4885MAPT 2283/4885 |
| US-20250084036-A1 | COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND THERAPEUTIC AND/OR PROPHYLACTIC DRUG | ALDH3A1, ALDH2, ALDH1A1 | PIK3CA 4283/4885MTOR 3481/4885MAPT 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.